In the Cartitude 1 trial, the strongest predictor of long-term remission with Siltacel was a lower burden of disease (measured by bone marrow percentage and soluble BCMA levels), rather than the number of prior treatments. This implies using CAR-T therapy earlier in the disease course is more effective.

Real-world data confirms that the favorable safety profile of CAR T-cell therapies like Obicell holds true in broad clinical practice. This has been a crucial factor in expanding eligibility to older patients, with successful treatments now being administered to individuals in their 70s and 80s.

Surprisingly, patients with high-risk cytogenetics, a typically poor prognostic factor in multiple myeloma, were equally represented in both the long-term remission group and the group that progressed after Siltacel treatment. This suggests CAR-T therapy may overcome traditional risk stratification.

For older, transplant-ineligible patients, well-tolerated, long-term regimens from trials like CFIUS shift the treatment goal. Success is defined as managing myeloma so effectively that patients are more likely to die of other age-related causes, effectively outliving their cancer.

The efficacy of Siltacel stems from a powerful initial expansion that eliminates cancer upfront. The CAR-T cells are often undetectable beyond six months, indicating their curative potential comes from an overwhelming initial response rather than persistent, long-term immune policing of the disease.

Five-year follow-up from the CARTITUDE-1 trial suggests a potential cure for multiple myeloma is achievable. With roughly one-third of heavily pretreated patients remaining in remission at five years—and some confirmed as MRD-negative—the concept of a cure is now part of the operational discussion among specialists, a monumental shift for a disease long considered incurable.

Traditional age cutoffs for AML therapy are becoming obsolete. A comprehensive fitness assessment, not just chronological age, should guide treatment, as some guidelines now classify patients as young as 55 as "older adults," a surprising shift for many clinicians.

Experts report successfully treating lymphoma patients as old as 92 with CAR-T, even those with mild cognitive impairment. This demonstrates that chronological age alone is not an absolute contraindication; functional status is a more critical determinant of eligibility for intensive therapies.

Without head-to-head trials, clinicians select between Obicell and Brexacel based on a practical algorithm. Patient factors like age and frailty, disease burden, and logistical concerns like product availability dictate the selection, with safer options prioritized for high-risk patients.